BioWorld

Oct. 31, 2003

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

A trio of biotech IPOs priced in succession, but the public money appears to be flowing conservatively, some industry observers think. (BioWorld Today) Read More

Alkermes' Risperidone Wins FDA Nod For Schizophrenia

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Aphton's Phase III Positive For G17DT Cancer Vaccine

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...